Scripps Research Institute: Calibr-Skaggs Announces Initial Dosing of a First-in-Class Regenerative Lung Medicine in a Phase 1 Trial for Idiopathic Pulmonary Fibrosis
October 31, 2024
October 31, 2024
LA JOLLA, California, Oct. 31 (TNSres) -- The Scripps Research Institute issued the following news on Oct. 30, 2024:
* * *
CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
* * *
The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung t . . .
* * *
CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
* * *
The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung t . . .